ClinicalTrials.gg
Drug

Tucidinostat clinical trials

Also written Chidamide, Epidaza, HBI-8000 and CS055.

studies test it
185
open now
89
in phase 3
18
first study started
2013

How each study uses tucidinostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tucidinostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tucidinostat
17
HDACi chidamide
3
HDACi
2
Cyclophosphamide
2

Brand

Epidaza
18

Development codes

HBI-8000
13
CS055
10

Other names

Chidamide
110

In one entry with another drug

Given together, or one or the other

CACAG+VEN
4
Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
3
HBI-8000 in combination with nivolumab
2
Chidamide combined with cisplatin
2

Studies by the year they started

185 studies that test it; most in 2022 (30)

Studies that test tucidinostat, by start year
YearStudies
20131
20142
20154
201616
201710
20189
201910
202012
202117
202230
202319
202424
202511
202620

By phase

A phase 1/2 study counts in both.

Phase 1
41
Phase 2
152
Phase 3
18
Phase 4
2
No phase
9

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 19 · Other 166

Sun Yat-sen University (20) · Chinese PLA General Hospital (11) · Ruijin Hospital (11) · Chipscreen Biosciences, Ltd. (9) · The First Affiliated Hospital of Soochow University (8) · HUYABIO International, LLC. (7) · Peking Union Medical College Hospital (7) · Tianjin Medical University Cancer Institute and Hospital (6)

Often tested with

Tested in the same studies.

Azacitidine (14) · Sintilimab (13) · Venetoclax (11) · Toripalimab (6) · Golidocitinib (6) · Cytarabine (5) · Aclacinomycins (5) · Rituximab (5)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Tucidinostat is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 19, 1 in phase 3

Studies that test tucidinostat, phase 3 first.

Studies

Open first, then newest update. How each study uses tucidinostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 185

See all 185 studies that test tucidinostat →

Given beside what is tested · 10 — tucidinostat is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with tucidinostat

Codes

What other systems call tucidinostat · ClinicalTrials.gg INT005587

  • MeSH (NLM) C547816N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideConfirmed NLM, Wikidata
  • UNII (FDA) 87CIC980Y0TUCIDINOSTATConfirmed FDA, NLM, Wikidata
  • Wikidata Q19903814tucidinostatConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C97263TucidinostatOne source FDA
  • DrugBank DB06334One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.